Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...

A collaborative research team has uncovered a previously unknown mechanism of action of yaku'amide B, a structurally complex peptidic natural product derived from deep-sea sponge found in the waters ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease. Unlike ...

Researchers developed FLAV-27, an epigenetic drug that inhibits G9a to restore gene expression in Alzheimer’s models. The treatment reduced amyloid and tau, improved cognition and synaptic function, ...

Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms, ...

This review systematically summarizes the research progress in Polyphenol self-assembled drug delivery systems (DDS), with a focused elaboration on their assembly mechanisms, functional advantages ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for ...